Cardiff Oncology, Inc.
CRDF
$2.41
-$0.03-1.23%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -25.77% | -46.83% | -3.21% | 17.02% | 50.93% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -25.77% | -46.83% | -3.21% | 17.02% | 50.93% |
| Cost of Revenue | 21.98% | 30.83% | 25.11% | 20.17% | 18.37% |
| Gross Profit | -22.82% | -32.87% | -25.69% | -20.23% | -17.92% |
| SG&A Expenses | 3.20% | 28.24% | 10.50% | 6.36% | -25.16% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.23% | 30.10% | 21.31% | 16.47% | 3.18% |
| Operating Income | -17.79% | -31.55% | -21.68% | -16.46% | -2.76% |
| Income Before Tax | -18.38% | -34.19% | -26.24% | -21.83% | -5.63% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.38% | -34.19% | -26.24% | -21.83% | -5.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.38% | -34.19% | -26.24% | -21.83% | -5.63% |
| EBIT | -17.79% | -31.55% | -21.68% | -16.46% | -2.76% |
| EBITDA | -18.03% | -31.93% | -21.97% | -16.68% | -2.73% |
| EPS Basic | 20.24% | 9.90% | -4.02% | -16.15% | -5.29% |
| Normalized Basic EPS | 20.22% | 9.86% | -4.06% | -16.16% | -5.26% |
| EPS Diluted | 20.24% | 9.90% | -4.02% | -16.15% | -5.29% |
| Normalized Diluted EPS | 20.22% | 9.86% | -4.06% | -16.16% | -5.26% |
| Average Basic Shares Outstanding | 48.41% | 48.90% | 21.35% | 4.90% | 0.33% |
| Average Diluted Shares Outstanding | 48.41% | 48.90% | 21.35% | 4.90% | 0.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |